This opportunity funds rigorous early-stage clinical trials aimed at developing innovative and safer therapeutic interventions for neurodegenerative diseases. Proposals should integrate active substances with complementary multidisciplinary approaches, ensure diverse patient cohorts, and promote data sharing and collaboration. The goal is to advance effective treatments that reduce disease burden and improve patient quality of life.
Eligible applicants include legal entities established in EU, Associated Countries, and the USA. Proposals must comply with admissibility conditions, page limits, and blind evaluation requirements. Specific eligibility details and country lists are provided in the Horizon Europe Work Programme annex
